AU2022267304A1 - Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female - Google Patents
Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female Download PDFInfo
- Publication number
- AU2022267304A1 AU2022267304A1 AU2022267304A AU2022267304A AU2022267304A1 AU 2022267304 A1 AU2022267304 A1 AU 2022267304A1 AU 2022267304 A AU2022267304 A AU 2022267304A AU 2022267304 A AU2022267304 A AU 2022267304A AU 2022267304 A1 AU2022267304 A1 AU 2022267304A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- dose
- administered
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181807P | 2021-04-29 | 2021-04-29 | |
| US63/181,807 | 2021-04-29 | ||
| PCT/US2022/026908 WO2022232494A1 (en) | 2021-04-29 | 2022-04-29 | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022267304A1 true AU2022267304A1 (en) | 2023-11-02 |
Family
ID=81748326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022267304A Pending AU2022267304A1 (en) | 2021-04-29 | 2022-04-29 | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240216396A1 (https=) |
| EP (1) | EP4329769A1 (https=) |
| JP (1) | JP2024515830A (https=) |
| CN (1) | CN117580580A (https=) |
| AU (1) | AU2022267304A1 (https=) |
| CA (1) | CA3217866A1 (https=) |
| IL (1) | IL307980A (https=) |
| MX (1) | MX2023012728A (https=) |
| WO (1) | WO2022232494A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2022
- 2022-04-29 US US18/557,705 patent/US20240216396A1/en active Pending
- 2022-04-29 CN CN202280045723.6A patent/CN117580580A/zh active Pending
- 2022-04-29 AU AU2022267304A patent/AU2022267304A1/en active Pending
- 2022-04-29 CA CA3217866A patent/CA3217866A1/en active Pending
- 2022-04-29 JP JP2023566515A patent/JP2024515830A/ja active Pending
- 2022-04-29 MX MX2023012728A patent/MX2023012728A/es unknown
- 2022-04-29 IL IL307980A patent/IL307980A/en unknown
- 2022-04-29 EP EP22724194.0A patent/EP4329769A1/en active Pending
- 2022-04-29 WO PCT/US2022/026908 patent/WO2022232494A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL307980A (en) | 2023-12-01 |
| JP2024515830A (ja) | 2024-04-10 |
| WO2022232494A1 (en) | 2022-11-03 |
| MX2023012728A (es) | 2023-11-08 |
| CN117580580A (zh) | 2024-02-20 |
| EP4329769A1 (en) | 2024-03-06 |
| CA3217866A1 (en) | 2022-11-03 |
| US20240216396A1 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022267304A1 (en) | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female | |
| EP4308162A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder | |
| KR20240148425A (ko) | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 | |
| US20240216395A1 (en) | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression | |
| JP2023038310A (ja) | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 | |
| KR20220112803A (ko) | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 | |
| JP2020530831A (ja) | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 | |
| MD3347002T2 (ro) | Tratamentul bolii Alzheimer într-o populație specifică de pacienți | |
| US10278977B2 (en) | Methods for treating hypersomnolence | |
| JP2023539567A (ja) | 神経活性ステロイドを含有する医薬組成物及びその使用 | |
| CN117098554A (zh) | 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇 | |
| CN117580581A (zh) | 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇 | |
| HK40096830A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| JP2025536721A (ja) | 強迫性障害の予防または治療のための低用量のドネペジルまたはその誘導体を使用した新規投与レジメン | |
| EP4673123A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2025146469A1 (en) | Treatment for the symptoms of menopause and perimenopause | |
| Kuschnir et al. | 273 fetal loss in severe asthma and posterior healthy pregnancy and birth with the use of omalizumab—case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SAGE THERAPEUTICS, LLC |